<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer - Vasconcellos, VF - 2020 | Cochrane Library</title> <meta content="Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer - Vasconcellos, VF - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009256.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer - Vasconcellos, VF - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009256.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009256.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer" name="citation_title"/> <meta content="Vitor F Vasconcellos" name="citation_author"/> <meta content="Instituto do Câncer do Estado de São Paulo (ICESP/FMUSP)" name="citation_author_institution"/> <meta content="Guilherme N Marta" name="citation_author"/> <meta content="Instituto do Câncer do Estado de São Paulo (ICESP/FMUSP)" name="citation_author_institution"/> <meta content="Edina MK da Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Aecio FT Gois" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Tiago B de Castria" name="citation_author"/> <meta content="Instituto do Câncer do Estado de São Paulo (ICESP/FMUSP)" name="citation_author_institution"/> <meta content="tiagobiachi@yahoo.com.br" name="citation_author_email"/> <meta content="Rachel Riera" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009256.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009256.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009256.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009256.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Carboplatin [therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy]; Cisplatin [therapeutic use]; Lung Neoplasms [*drug therapy]; Nausea [chemically induced]; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Vomiting [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009256.pub3&amp;doi=10.1002/14651858.CD009256.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009256\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009256\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","fr","zh_HANS","fa","ko","ms","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009256.pub3",title:"Cisplatin versus carboplatin in combination with third\\u2010generation drugs for advanced non\\u2010small cell lung cancer",firstPublishedDate:"Jan 13, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Lung Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009256.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009256.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009256.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009256.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009256.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009256.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009256.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009256.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009256.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009256.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15767 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009256.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0118"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0048"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0049"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-sec-0112"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/appendices#CD009256-sec-0123"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/table_n/CD009256StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/table_n/CD009256StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0002">Vitor F Vasconcellos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0003">Guilherme N Marta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0004">Edina MK da Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0005">Aecio FT Gois</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Tiago B de Castria</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information#CD009256-cr-0007">Rachel Riera</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information/en#CD009256-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009256.pub3">https://doi.org/10.1002/14651858.CD009256.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009256-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009256-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009256-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009256-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009256-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009256-abs-0012">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009256-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009256-abs-0001" lang="en"> <section id="CD009256-sec-0001"> <h3 class="title" id="CD009256-sec-0001">Background</h3> <p>Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death in both sexes worldwide. Approximately 50% of those diagnosed with lung cancer will have locally advanced or metastatic disease and will be treated in a palliative setting. Platinum‐based combination chemotherapy has benefits in terms of survival and symptom control when compared with best supportive care. </p> </section> <section id="CD009256-sec-0002"> <h3 class="title" id="CD009256-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of carboplatin‐based chemotherapy when compared with cisplatin‐based chemotherapy, both in combination with a third‐generation drug, in people with advanced non‐small cell lung cancer (NSCLC). To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third‐generation drug. </p> </section> <section id="CD009256-sec-0003"> <h3 class="title" id="CD009256-sec-0003">Search methods</h3> <p>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL; 13 January 2019), MEDLINE (via PubMed) (1966 to 13 January 2019), and Embase (via Ovid) (1974 to 13 January 2019). In addition, we handsearched the proceedings of the American Society of Clinical Oncology Meetings (January 1990 to September 2018) and reference lists from relevant resources. </p> </section> <section id="CD009256-sec-0004"> <h3 class="title" id="CD009256-sec-0004">Selection criteria</h3> <p>Randomised clinical trials (RCTs) comparing regimens with carboplatin or cisplatin combined with a third‐generation drug in people with locally advanced or metastatic NSCLC. We accepted any regimen and number of cycles that included these drugs, since there is no widely accepted standard regimen. </p> </section> <section id="CD009256-sec-0005"> <h3 class="title" id="CD009256-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the search results, and a third review author resolved any disagreements. The primary outcomes were overall survival and health‐related quality of life. The secondary outcomes were one‐year survival rate, objective response rate and toxicity. </p> </section> <section id="CD009256-sec-0006"> <h3 class="title" id="CD009256-sec-0006">Main results</h3> <p>In this updated review, we located one additional RCT, for a total of 11 included RCTs (5088 participants, 4046 of whom were available for meta‐analysis). There was no difference in overall survival (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.82 to 1.20; 10 RCTs; 2515 participants; high‐quality evidence); one‐year survival rate (risk ratio (RR) 0.98, 95% CI 0.89 to 1.08; I<sup>2</sup> = 17%; 4004 participants; all 11 RCTs; high‐quality evidence); or response rate (RR 0.89, 95% CI 0.79 to 1.00; I<sup>2</sup> = 12%; all 11 RCTs; 4020 participants; high‐quality evidence). A subgroup analysis comparing carboplatin with different doses of cisplatin found an overall survival benefit in favour of carboplatin‐based regimens when compared to cisplatin at lower doses (40 to 80 mg/m<sup>2</sup>) (HR 1.15, 95% CI 1.03 to 1.28; 6 RCTs; 2508 participants), although there was no overall survival benefit when carboplatin‐based chemotherapy was compared to cisplatin at higher doses (80 to 100 mg/m<sup>2</sup>) (HR 0.93, 95% CI 0.83 to 1.04; I<sup>2</sup> = 0%; 4 RCTs; 1823 participants). Carboplatin caused more thrombocytopenia (RR 2.46, 95% CI 1.49 to 4.04; I<sup>2</sup> = 68%; 10 RCTs; 3670 participants) and was associated with more neurotoxicity (RR 1.42, 95% CI 0.91 to 2.23; I<sup>2</sup> = 0%, 5 RCTs; 1489 participants), although we believe this last finding is probably related to a confounding factor (higher dose of paclitaxel in the carboplatin‐containing treatment arm of a large study included in the analysis). There was no statistically significant difference in renal toxicity (RR 0.52, 95% CI 0.19 to 1.45; I<sup>2</sup> = 3%; 3 RCTs; 1272 participants); alopecia (RR 1.11, 95% CI 0.73 to 1.68; I<sup>2</sup> = 0%; 2 RCTs; 300 participants); anaemia (RR 1.37, 95% CI 0.79 to 2.38; I2 = 77%; 10 RCTs; 3857 participants); and neutropenia (RR 1.18, 95% CI 0.85 to 1.63; I<sup>2</sup> = 94%; 10 RCTs; 3857 participants) between cisplatin‐based chemotherapy and carboplatin‐based chemotherapy regimens. Two RCTs performed a health‐related quality of life analysis; however, as they used different methods of measurement we were unable to perform a meta‐analysis. One RCT reported comparative health‐related quality of life data between cisplatin and carboplatin‐containing arms but found no significant differences in global indices of quality of life, including global health status or functional scales. </p> <p>In this Cochrane review, we found that the quality of evidence was high for overall survival, one‐year survival rate and response rate but moderate quality evidence for the other outcomes measured. </p> </section> <section id="CD009256-sec-0007"> <h3 class="title" id="CD009256-sec-0007">Authors' conclusions</h3> <p>Advanced NSCL patients treated with carboplatin or cisplatin doublet with third‐generation chemotherapy drugs showed equivalent overall survival, one‐year survival, and response rate. Regarding adverse events, carboplatin caused more thrombocytopenia, and cisplatin caused more nausea/vomiting. Therefore, in this palliative therapeutic intent, the choice of the platin compound should take into account the expected toxicity profile, patient's comorbidities and preferences. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009256-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009256-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009256-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009256-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009256-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009256-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009256-abs-0013">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009256-abs-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009256-abs-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009256-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009256-abs-0004" lang="en"> <h3>Comparing carboplatin‐based chemotherapy with cisplatin‐based chemotherapy in the treatment of people with advanced lung cancer </h3> <p><b>Review question</b> </p> <p>Is carboplatin more effective and less toxic than cisplatin in the treatment of people with advanced non‐small cell lung cancer? </p> <p><b>Background</b> </p> <p>Lung cancer is the leading cause of cancer death, and more than a half of people found to have the cancer have incurable disease at diagnosis. Non‐small cell is the most common type of lung cancer, corresponding to approximately 85% of all lung cancer cases. Despite recent advances in targeted therapies and immunotherapy, platinum‐based chemotherapy remains a useful and accessible option with well‐established survival benefits for people with advanced non‐small cell lung cancer. Although treatment regimens including cisplatin or carboplatin plus another agent are widely used, they can be associated with undesirable side effects. The aim of this systematic review was to determine which of these two frequently used drugs was more effective and caused fewer side effects. </p> <p><b>Study characteristics</b> </p> <p>We found 11 trials (including 4046 people) that compared cisplatin with carboplatin, both combined with another modern drug, called a third‐generation drug. </p> <p><b>Key results</b> </p> <p>The drugs were equally effective at prolonging survival, but the toxicity profile was different. Carboplatin caused a greater decrease in the number of platelets (which control clotting) in the blood. </p> <p><b>Quality of evidence</b> </p> <p>In this Cochrane review, we found that the quality of evidence was high for overall survival, one‐year survival rate and response rate but moderate quality evidence for the other outcomes measured. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009256-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009256-sec-0118"></div> <h3 class="title" id="CD009256-sec-0119">Implications for practice</h3> <section id="CD009256-sec-0119"> <p>Our findings suggest several implications for practice. In our meta‐analysis, carboplatin and cisplatin had equivalent overall survival, one‐year survival, and response rate. When combined with gemcitabine or paclitaxel, carboplatin had the same response rate as cisplatin. When platinum compounds were combined with docetaxel, a higher response rate for cisplatin‐containing arms was demonstrated in one of the studies. The clinical decision about which platinum compound to use should thus take into account its adverse effects profile as well as the drug with which it will be combined. </p> <p>With respect to toxicity, carboplatin caused more thrombocytopenia, and cisplatin caused more nausea/vomiting, as found in previous meta‐analyses. Since health‐related quality of life was not directly compared between cisplatin and carboplatin treatment, the approach for these patients has to be individualised. </p> </section> <h3 class="title" id="CD009256-sec-0120">Implications for research</h3> <section id="CD009256-sec-0120"> <p>As previous review authors have found, we could not perform a meta‐analysis of quality of life data. Many trials have evaluated quality of life, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) score has been the most popular score in some of these trials. It is crucial to consider quality of life in future randomised clinical trials. </p> <p>Finally, although our review has shown that carboplatin has at least equivalent effectiveness to cisplatin, it is important to define the role of both drugs combined with a third‐generation drug plus new drugs, such as monoclonal antibodies and immune checkpoint inhibitors. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009256-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009256-sec-0043"></div> <div class="table" id="CD009256-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> combination with third‐generation drugs for advanced non‐small cell lung cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> carboplatin‐containing chemotherapy<br/> <b>Comparison:</b> cisplatin‐containing chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with carboplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival</p> <p>(baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Low risk of death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>HR 0.99<br/> (0.82 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2515<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1000<br/> (254 to 348) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>High risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/> (388 to 512) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1‐year survival rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.89 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4004<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/> (330 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.79 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4020<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/> (219 to 277) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.42 (0.91 to 2.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3857<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000<br/> (57 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (1.49 to 4.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3857<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/> (66 to 180) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV renal toxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/> (0.19 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1272<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (4 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Renal toxicity rates were only reported by five included trials.<br/> <sup>2</sup>The heterogeneity found in this analysis was due to data from the <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> trial, so that when data from this trial were excluded, the result remained similar, but without significant heterogeneity (RR 2.00, 95% CI 1.37 to 2.91; I<sup>2</sup> = 21%).<br/> <sup>3</sup>Renal toxicity rates were only reported by three included trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009256-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009256-sec-0044"></div> <section id="CD009256-sec-0045"> <h3 class="title" id="CD009256-sec-0045">Description of the condition</h3> <p>Lung cancer is the most commonly diagnosed cancer (11.6% of total cases) and the leading cause of cancer death (18.4% of total cancer deaths) in both sexes worldwide (<a href="./references#CD009256-bbs2-0023" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68:394–424. ">GLOBOCAN 2018</a>). The vast majority (about 85%) of lung cancers are pathologic classified as non‐small cell type, and more than a half of patients are diagnosed with incurable locally advanced or metastatic disease (<a href="./references#CD009256-bbs2-0036" title="NooneAM , CroninKA , AltekruseSF , HowladerN , LewisDR , PetkovVI , et al. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results program, 1992‐2013. Cancer Epidemiology, Biomarkers &amp; Prevention2017; Vol. 26, issue 4:632‐41. [DOI: 10.1158/1055‐9965.EPI‐16‐0520] ">Noone 2018</a>). </p> </section> <section id="CD009256-sec-0046"> <h3 class="title" id="CD009256-sec-0046">Description of the intervention</h3> <p>Chemotherapy in advanced non‐small cell lung cancer (NSCLC) has been integrative part of treatment for several decades. In the 1990s, a meta‐analysis of 52 randomised clinical trials (RCTs) showed that treatment with cisplatin‐based chemotherapy resulted in an increased median survival by six weeks compared with best supportive care in people with NSCLC (<a href="./references#CD009256-bbs2-0037" title="NSCLC Collaborative Group. Chemotherapy in non‐small cell lung cancer: a meta‐analysis using updated data on individual patients from 52 randomised clinical trials. BMJ1995;311(7010):899‐909. ">NSCLC Collaborative Group 1995</a>). Evidence accumulated since then has indicated that a platinum agent in combination with a third‐generation chemotherapy agent is the standard first‐line treatment (<a href="./references#CD009256-bbs2-0027" title="HannaN , JohnsonD , TeminS , BakerSJr , BrahmerJ , EllisPM , et al. Systemic therapy for stage IV non‐small‐cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology2017;35(30):3484‐515. [PUBMED: 28806116] ">Hanna 2017</a>). </p> <p>More recently, the development of effective targeted therapies and immune checkpoint inhibitors has revolutionised the management of advanced solid tumours, including NSCLC treatment (<a href="./references#CD009256-bbs2-0049" title="VasconcellosVF , ColliLM , AwadaA , deCastro JuniorG . Precision oncology: as much expectations as limitations. ecancermedicalscience2018; Vol. 12:ed86. [PUBMED: 30679954] ">Vasconcellos 2018</a>). However, cisplatin‐based chemotherapy still has a main role in the first and subsequent lines of therapy (<a href="./references#CD009256-bbs2-0034" title="LisbergA , GaronEB . Does platinum‐based chemotherapy still have a role in first‐line treatment of advanced non‐small‐cell lung cancer?. Journal of Clinical Oncology2019;37(7):529‐36. [PUBMED: 30676857] ">Lisberg 2019</a>), and modern therapies are not available worldwide because of global variation in access to cancer treatment (<a href="./references#CD009256-bbs2-0021" title="deSouzaJA , HuntB , AsirwaFC , AdebamowoC , LopesG . Global health equity: cancer care outcome disparities in high‐, middle‐, and low‐income countries. Journal of Clinical Oncology2016;34(1):6‐13. [PUBMED: 26578608] ">de Souza 2016</a>). </p> <p>It is well known that cisplatin causes a number of significant side effects including nausea and vomiting, alopecia, neutropenia, ototoxicity, neurotoxicity, and renal function impairment (<a href="./references#CD009256-bbs2-0038" title="O’DwyerPJ , CalvertAH . Platinum analogs. In: DeVitaVT , LawrenceTS , RosenbergSA editor(s). Cancer: principles and practice of oncology. 10th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2015:199‐208. ">O'Dwyer 2015</a>). Despite efforts to identify genetic predictors of the effectiveness and toxicity of cytotoxic therapies, to this point there are no robust data that can be used in clinical practice to guide the best subgroup of patients to receive cisplatin (<a href="./references#CD009256-bbs2-0041" title="Perez‐RamirezC , Canadas‐GarreM , MolinaMA , RoblesAI , Faus‐DaderMJ , Calleja‐HernandezMA . Contribution of genetic factors to platinum‐based chemotherapy sensitivity and prognosis of non‐small cell lung cancer. Mutation Research2017;771:32‐58. [PUBMED: 28342452] ">Perez‐Ramirez 2017</a>). As a consequence, carboplatin has emerged as a reasonable and potentially more tolerable alternative, since it has been associated with myelotoxicity (particularly thrombocytopenia) but less nephrotoxicity and neurotoxicity (<a href="./references#CD009256-bbs2-0029" title="HoGY , WoodwardN , CowardJIG . Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology2016;102:37‐46. [DOI: 10.1016/j.critrevonc.2016.03.014] ">Ho 2016</a>). </p> <p>Since 1990, more than 20 trials have compared cisplatin with carboplatin in individuals with advanced NSCLC, whilst only a few trials have compared regimens containing a third‐generation drug such as irinotecan, paclitaxel, docetaxel, gemcitabine, and vinorelbine. For example, Schiller and colleagues published a landmark phase III trial that compared cisplatin plus paclitaxel versus carboplatin plus paclitaxel. They found similar survival and response rates but less toxicity with carboplatin plus paclitaxel, although quality of life (QoL) was not assessed (<a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>). </p> <p>Previous systematic reviews have not found an overall survival difference between platinum analogs used in modern doublet‐regimens in people with advanced NSCLC, although some contradictory results regarding overall response rate and safety profile have been reported (<a href="./references#CD009256-bbs2-0019" title="ArdizzoniA , BoniL , TiseoM , FossellaFV , SchillerJH , PaesmansM , et al. Cisplatin versus carboplatin‐based chemotherapy in first‐line treatment of advanced non‐small‐cell lung cancer: an individual patient data meta‐analysis. Journal of the National Cancer Institute2007;99(11):847‐57. ">Ardizzoni 2007</a>; <a href="./references#CD009256-bbs2-0020" title="BaggstromM , StinchcombeT , FriedD , PooleC , HensingT , SocinskiM . Third‐generation chemotherapy agents in the treatment of advanced non‐small cell lung cancer: a meta‐analysis. Journal of Thoracic Oncology2007;2(9):845‐53. ">Baggstrom 2007</a>; <a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a>; <a href="./references#CD009256-bbs2-0031" title="JiangJ , LiangX , ZhouX , HuangR , ChuZ . A meta‐analysis of randomized controlled trials comparing carboplatin‐based to cisplatin‐based chemotherapy in advanced non‐small cell lung cancer. Lung Cancer2007;57(3):348‐58. ">Jiang 2007</a>; <a href="./references#CD009256-bbs2-0051" title="deCastriaTB , daSilvaEM , GoisAF , RieraR . Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2] ">de Castria 2013</a>). Another important limitation of these previous studies is the inadequate QoL assessment due to the low number and poor quality of trials reporting QoL analysis (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>; <a href="./references#CD009256-bbs2-0039" title="PaccagnellaA , FavarettoA , OnigaF , BarbieriF , CeresoliG , TorriW , et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer2004;43(1):83‐91. ">Paccagnella 2004</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>). </p> </section> <section id="CD009256-sec-0047"> <h3 class="title" id="CD009256-sec-0047">Why it is important to do this review</h3> <p>In view of the still important role of platinum doublet‐based chemotherapy in palliative advanced NSCLC patients, we aimed to update our previous Cochrane meta‐analysis in order to better elucidate and clarify the requirement to use platinum salts content regimens with high efficiency and better safety profile. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009256-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009256-sec-0048"></div> <p>To assess the effectiveness and safety of carboplatin‐based chemotherapy compared with cisplatin‐based chemotherapy, both in combination with a third‐generation drug, in people with advanced NSCLC. </p> <p>To compare the QoL of people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third‐generation drug. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009256-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009256-sec-0049"></div> <section id="CD009256-sec-0050"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009256-sec-0051"> <h4 class="title">Types of studies</h4> <p>RCTs that compared regimens with cisplatin or carboplatin in combination with a third‐generation drug (i.e. docetaxel, paclitaxel, vinorelbine, gemcitabine, or irinotecan) in people with advanced NSCLC. We excluded non‐randomised and quasi‐randomised studies. </p> </section> <section id="CD009256-sec-0052"> <h4 class="title">Types of participants</h4> <p>People with pathologically confirmed NSCLC, with metastatic disease, or pleural or pericardial effusion (stage IIIB or IV; <a href="./references#CD009256-bbs2-0048" title="SobinLH , WittekindC . Union for International Cancer Control (UICC), TNM Classification of Malignant Tumours. 6th Edition. Vol. 1, New York: Wiley‐Liss, 2002. ">Sobin 2002</a>). </p> </section> <section id="CD009256-sec-0053"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009256-list-0001"> <li> <p>Cisplatin plus gemcitabine versus carboplatin plus gemcitabine.</p> </li> <li> <p>Cisplatin plus docetaxel versus carboplatin plus docetaxel.</p> </li> <li> <p>Cisplatin plus paclitaxel versus carboplatin plus paclitaxel.</p> </li> <li> <p>Cisplatin plus vinorelbine versus carboplatin plus vinorelbine.</p> </li> <li> <p>Cisplatin plus irinotecan versus carboplatin plus irinotecan.</p> </li> </ul> </p> <p>We included trials comparing these compounds for any number of cycles or treatment schedules. </p> </section> <section id="CD009256-sec-0054"> <h4 class="title">Types of outcome measures</h4> <section id="CD009256-sec-0055"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009256-list-0002"> <li> <p>Overall survival.</p> </li> <li> <p>Health‐related quality of life (HRQoL), assessed by a validated scale.</p> </li> </ul> </p> </section> <section id="CD009256-sec-0056"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009256-list-0003"> <li> <p>One‐year survival rate.</p> </li> <li> <p>Objective response rate, classified according to the Response Evaluation Criteria in Solid Tumors (RECIST) (<a href="./references#CD009256-bbs2-0022" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228‐47. ">Eisenhauer 2009</a>). </p> </li> <li> <p>Drug toxicities (according to the National Cancer Institute Common Toxicity Criteria v2.0) (<a href="./references#CD009256-bbs2-0035" title="National Cancer Institute. Common toxicity criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4‐30‐992.pdf (accessed 26 June 2013). ">NCI Common Toxicity Criteria</a>). We analysed trials reporting toxicity data as events per cycle or events per participant. </p> </li> </ul> </p> </section> </section> </section> <section id="CD009256-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <p>Our search for trials was performed in accordance with the Cochrane Lung Cancer Review Group recommendations, and there were no limits regarding study publication date or language. </p> <section id="CD009256-sec-0058"> <h4 class="title">Electronic searches</h4> <p>We performed electronic searches of the following databases:</p> <p> <ol id="CD009256-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (issue 1, 2019).</p> </li> <li> <p>MEDLINE (via PubMed) (1966 to 13 January 2019);</p> </li> <li> <p>Embase (via Ovid) (1974 to 13 January 2019);</p> </li> </ol> </p> <p>The search strategies used for each database are presented in <a href="./appendices#CD009256-sec-0124">Appendix 1</a>. </p> </section> <section id="CD009256-sec-0059"> <h4 class="title">Searching other resources</h4> <p>We carried out a manual search of the Proceedings of the American Society of Clinical Oncology Meetings (1990 to 2018). We searched the reference lists of relevant studies and contacted study authors to obtain information about ongoing or non‐published studies. </p> </section> </section> <section id="CD009256-sec-0060"> <h3 class="title" id="CD009256-sec-0060">Data collection and analysis</h3> <section id="CD009256-sec-0061"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GNM and VFV) independently examined the abstracts of studies identified by the search. We obtained full‐text versions of all those articles deemed potentially relevant. A third review author (TBC) resolved any disagreements. </p> </section> <section id="CD009256-sec-0062"> <h4 class="title">Data extraction and management</h4> <p>We extracted and recorded data on data extraction forms. Two review authors (GNM and VFV) independently developed and piloted the forms and conducted full data extraction. A third review author (TBC) resolved any disagreements. We included the following information from individual studies on the data extraction forms: </p> <p> <ul id="CD009256-list-0005"> <li> <p>publication details;</p> </li> <li> <p>study design, setting, inclusion/exclusion criteria, method of allocation, allocation concealment, blinding, risk of bias; </p> </li> <li> <p>participant population (e.g. age, type of surgical procedure, type of tumour);</p> </li> <li> <p>details of intervention: doses, regimen, scheme, duration;</p> </li> <li> <p>outcome measures;</p> </li> <li> <p>withdrawals, duration and method of follow‐up, proportion of follow‐up;</p> </li> <li> <p>type of analyses (e.g. intention‐to‐treat, modified intention‐to‐treat).</p> </li> </ul> </p> </section> <section id="CD009256-sec-0063"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (GNM and VFV) independently assessed risk of bias for each study using the Cochrane 'Risk of bias' tool (<a href="./references#CD009256-bbs2-0028" title="HigginsJPT , GreenS , editor(s) . Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We assigned 'low risk of bias', 'high risk of bias', or 'unclear risk of bias' for each 'Risk of bias' domain using the specific questions detailed below and in (<a href="#CD009256-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009256-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009256-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p> <ul id="CD009256-list-0006"> <li> <p>Sequence generation: was the allocation sequence adequately generated?</p> </li> <li> <p>Allocation concealment: was allocation adequately concealed?</p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors: was knowledge of the allocated interventions adequately prevented during the study? </p> </li> <li> <p>Incomplete outcome data: were outcome data adequately assessed and accounted for?</p> </li> <li> <p>Selective outcome reporting: were reports of the study free of the suggestion of selective outcome reporting? </p> </li> <li> <p>Other potential threats to validity: was the study apparently free from other problems that could put it at risk of bias? </p> </li> </ul> </p> </section> <section id="CD009256-sec-0064"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RRs) and 95% confidence intervals (CI) for dichotomous outcomes. When focusing on grade III or IV toxic events (<a href="./references#CD009256-bbs2-0035" title="National Cancer Institute. Common toxicity criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4‐30‐992.pdf (accessed 26 June 2013). ">NCI Common Toxicity Criteria</a>), an RR value greater than one indicated that the carboplatin‐based regimen was more toxic than the cisplatin‐based regimen. </p> <p>For time‐to‐event outcomes, we presented hazard ratio (HR) with 95% CIs where appropriate. For continuous outcomes we planned to use mean difference (MD). </p> </section> <section id="CD009256-sec-0065"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual. We only included RCTs in this review. We found no cross‐over or cluster‐randomised trials. </p> </section> <section id="CD009256-sec-0066"> <h4 class="title">Dealing with missing data</h4> <p>If the data were missing to the extent that we could not add the study to the meta‐analysis and we were unable to obtain the data, we presented the findings and discussed them in the main text of the review. </p> </section> <section id="CD009256-sec-0067"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated statistical heterogeneity amongst studies using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic. We considered an I<sup>2</sup> value greater than 50% as substantial heterogeneity. </p> </section> <section id="CD009256-sec-0068"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted study authors to request full data sets or to establish reasons for the non‐reporting of some data outcomes. We performed searches for the protocols of included trials. </p> <p>We planned to create and assess a funnel plot to investigate small‐study biases. In interpreting funnel plots, we planned to investigate possible reasons for funnel plot asymmetry as outlined in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and relate this to the findings of our review. </p> </section> <section id="CD009256-sec-0069"> <h4 class="title">Data synthesis</h4> <p>We summarised data through the forest plot graphics produced by Review Manager 5 (<a href="./references#CD009256-bbs2-0044" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), using a random‐effects model by default, since clinical or methodological diversity, or both, amongst studies was expected. </p> <p>We presented a narrative summary of the results of individual studies and discussed the results where data aggregation was not possible. </p> <section id="CD009256-sec-0070"> <h5 class="title">GRADE and 'Summary of findings' tables</h5> <p>For this update, we created a 'Summary of findings' table using all the outcomes stated in the <a href="#CD009256-sec-0054">Types of outcome measures</a> section. </p> <p>Two review authors (VFV and GNM) independently assessed the certainty of the evidence. We used the GRADE criteria (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to evaluate the certainty of the evidence of the studies that contribute data to the meta‐analyses of outcomes. We assessed the certainty of the evidence as either high, moderate, low, or very low. We used the methods and recommendations described in Section 8.5 and 8.7 and Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009256-bbs2-0028" title="HigginsJPT , GreenS , editor(s) . Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD009256-bbs2-0047" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. .. ">Schünemann 2011</a>). We used GRADEpro GDT software to create the 'Summary of findings' tables (<a href="./references#CD009256-bbs2-0024" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro Guideline Development Tool. Hamilton (ON).: McMaster University (developed by Evidence Prime, Inc.), 2015. Available at gradepro.org. ">GRADEpro GDT</a>). We explained all decisions to downgrade the certainty of the evidence using footnotes and provided comments to aid in the reader's understanding of the review where needed. </p> </section> </section> <section id="CD009256-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analysis for the primary outcomes:</p> <p> <ul id="CD009256-list-0007"> <li> <p>different combined drug (gemcitabine, paclitaxel, and docetaxel, since we expected different effects when different drugs were combined with cisplatin or carboplatin); </p> </li> <li> <p>different dose ranges of cisplatin: lower (40 to 80 mg/m<sup>2</sup>) and higher (80 to 100 mg/m<sup>2</sup>). These subgroups and dose limits were proposed by the authors before the search and were based on the most frequently used dose of cisplatin in current trials (75 to 80 mg/mL). </p> </li> </ul> </p> </section> <section id="CD009256-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses for the primary outcomes to assess the robustness of the overall results: </p> <p> <ul id="CD009256-list-0008"> <li> <p>excluding trials with high risk of detection or selection bias;</p> </li> <li> <p>random‐effects versus fixed‐effect model;</p> </li> <li> <p>only phase III trials: since response to therapy was previously overestimated in phase II trials, analysis of efficacy (response rate and survival data) should be considered exploratory in such trials (<a href="./references#CD009256-bbs2-0025" title="GreenS , BenedettiJ , CrowleyJ . Clinical trials in oncology. 2nd Edition. Boca Raton, FL: Chapman &amp; Hall/CRC, 2003. ">Green 2003</a>). We carried out a sensitivity analysis excluding phase II trials. </p> </li> </ul> </p> <section id="CD009256-sec-0073"> <h5 class="title">Interpreting results and reaching conclusions</h5> <p>We followed the recommendations proposed by <a href="./references#CD009256-bbs2-0047" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. .. ">Schünemann 2011</a> for interpreting findings and carefully distinguished between lack of evidence of effect and lack of effect. We based our conclusions only on the results from the quantitative or narrative synthesis of the studies included in this review. We did not draw recommendations for practice. Our suggestions for further studies were based on the remaining uncertainties in the area. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009256-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009256-sec-0074"></div> <section id="CD009256-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD009256-sec-0076"> <h4 class="title">Results of the search</h4> <p>Our updated search strategy found 1750 new records: 257 in CENTRAL, 294 in MEDLINE, and 1199 in Embase. We considered nine records to be potentially eligible for our systematic review. We excluded a further seven manuscripts after full‐text analysis. A summary of the search process is provided in <a href="#CD009256-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009256-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Updated meta‐analysis study flow diagram." data-id="CD009256-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Updated meta‐analysis study flow diagram.</p> </div> </div> </div> </section> <section id="CD009256-sec-0077"> <h4 class="title">Included studies</h4> <p>In addition to the 10 RCTs included in the previous version of this meta‐analysis (<a href="./references#CD009256-bbs2-0051" title="deCastriaTB , daSilvaEM , GoisAF , RieraR . Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2] ">de Castria 2013</a>), we included one new RCT, <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a>, and the final publication of the British Thoracic Oncology Group (BTOG2) trial, whose data had been included in the original version of this meta‐analysis (<a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>). Data from 71 participants were thus added to the 10 RCTs included in the original version of the review, totalling 5088 participants, of which data from 4046 were available for meta‐analysis. </p> <p>All trials were conducted in people with locally advanced or metastatic NSCLC and no important comorbidities. The included trials used gemcitabine (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>; <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>; <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a>; <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a>), paclitaxel (<a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>; <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>), or docetaxel (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>), in combination with a platinum compound. </p> <p>All of the study authors specified inclusion criteria, but exclusion criteria were not cited in two Chinese trials (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>). Exclusion criteria included pregnancy, current organ dysfunction, and symptomatic central nervous system metastases (asymptomatic was allowed in some trials). Details of the included trials are provided in the <a href="./references#CD009256-sec-0133" title="">Characteristics of included studies</a> tables. </p> <p>In a controlled, open‐label trial, <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a> randomised 71 people with squamous NSCLC and with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 to 2 to receive either gemcitabine (1000 mg/m<sup>2</sup>) on days one and eight plus carboplatin (area under the curve (AUC) 5 mg/mL X min) on day one or gemcitabine (1000 mg/m<sup>2</sup>) on days one and eight plus cisplatin (40 mg/m<sup>2</sup>) on days one and eight. The treatments were repeated every three weeks for up to six cycles. </p> <p><a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> randomised 1363 people with ECOG PS 0 to 2 to receive gemcitabine (1250 mg/m<sup>2</sup>) on days one and eight and cisplatin (80 mg/m<sup>2</sup>) on day one, every three weeks or gemcitabine (1250 mg/m<sup>2</sup>) and cisplatin (50 mg/m<sup>2</sup>) on day one, every three weeks or gemcitabine (1250 mg/m<sup>2</sup>) and carboplatin (AUC 6 mg/mL X min) on day one, every three weeks. This was a phase III trial with three arms (one arm with carboplatin and the other two arms with cisplatin at different doses). For the purpose of the analysis, dichotomous data (such as toxicity, response rate, and overall survival in one year) from cisplatin‐based arms were combined to create a single group of cisplatin and thus a single pair‐wise comparison. Since combining data from the arms with different doses of cisplatin was not possible for overall survival analysis, data from this study were excluded from the main overall survival analysis (<a href="./references#CD009256-fig-0007" title="">Analysis 1.1</a>), but data from each arm were included in the overall survival subgroup analysis that evaluated cisplatin at different doses (<a href="./references#CD009256-fig-0012" title="">Analysis 2.1</a>). </p> <p>In a phase II trial, <a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a> randomised 40 people to receive gemcitabine (1000 mg/m<sup>2</sup>) on days one and eight and carboplatin (AUC 4 to 6 mg/mL X min) on day one or gemcitabine (1000 mg/m<sup>2</sup>) on days one and eight and cisplatin (30 to 40 mg/m<sup>2</sup>) on days one to three. Treatments were repeated every three weeks. The study authors included people with a Karnofsky performance status (PS) of 40 or higher. </p> <p><a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a> studied 81 people aged 70 years or older, PS 0 to 2 on the World Health Organization (WHO) scale and with no signs or symptoms of brain metastases. Participants were randomised to paclitaxel (160 mg/m<sup>2</sup>) on day one and carboplatin (AUC 6 mg/mL X min) on day one or paclitaxel (160 mg/m<sup>2</sup>) on day one and cisplatin (60 mg/m<sup>2</sup>) on day one. Treatments were repeated every three weeks. </p> <p><a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> published results of a phase III trial comparing regimens of chemotherapy in 1218 participants with locally advanced or metastatic NSCLC with a Karnofsky PS of 70 or higher and no significant comorbidities. Participants were randomised to receive docetaxel (75 mg/m<sup>2</sup>) on day one and cisplatin (75 mg/m<sup>2</sup>) on day one or docetaxel (75 mg/m<sup>2</sup>) on day one and intravenous carboplatin (AUC 6 mg/mL X min) on day one. Treatments were repeated every three weeks. We did not use a third treatment arm (vinorelbine plus cisplatin) in the analysis because there was no parallel arm with vinorelbine and carboplatin. </p> <p>In <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>, 120 people with ECOG PS 0 to 2 and a life expectancy greater than 12 weeks were eligible to receive gemcitabine (1200 mg/m<sup>2</sup>) on days one and eight and cisplatin (80 mg/m<sup>2</sup>) on day two or gemcitabine (1200 mg/m<sup>2</sup>) on days one and eight and carboplatin (AUC 5 mg/mL X min) on day two. Treatments were repeated every three weeks. People with symptomatic central nervous system metastases were excluded. </p> <p><a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a> published the results of a phase III trial of 618 people with a ECOG PS 0 to 2 who were able to understand the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30). Participants received paclitaxel (200 mg/m<sup>2</sup>) and cisplatin (80 mg/m<sup>2</sup>) or paclitaxel (200 mg/m<sup>2</sup>) and carboplatin (AUC 6 mg/mL X min). Treatments were repeated every three weeks. The primary outcome was response rate and the secondary outcomes included the EORTC QLQ‐C30 and the EORTC Quality of Life Lung Cancer supplement 13 (QLQ‐LC13). </p> <p><a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a> published the results of a phase III trial with 1207 participants. Initially people with an ECOG PS 0 to 2 were eligible for enrolment, but the study design was amended after the enrolment of 66 people with PS 2 to exclude those participants due to the high rate of serious adverse events. Participants were randomised to receive paclitaxel (135 mg/m<sup>2</sup> infusion over 24 hours) on day one and cisplatin (75 mg/m<sup>2</sup>) on day two or paclitaxel (225 mg/m<sup>2</sup> infusion over three hours) on day one and carboplatin (AUC 6 mg/mL X min) on day one. Treatments were repeated every three weeks. We did not analyse arms two and three of the study in this review because the regimens used did not fulfil our inclusion criteria. A total of 1155 people were analysed. </p> <p><a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a> performed a phase II trial with 68 people, all of whom had an ECOG PS 2, randomising them to paclitaxel (135 mg/m<sup>2</sup> infusion over 24 hours) on day one and cisplatin (75 mg/m<sup>2</sup>) on day two or paclitaxel (225 mg/m<sup>2</sup> infusion over three hours) on day one and carboplatin (AUC 6 mg/mL X min) on day one. Treatments were repeated every three weeks. We excluded arms two and three of this trial because the regimens used did not fulfil our inclusion criteria. The primary outcomes of this trial were toxicity and adverse events. </p> <p><a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a> randomised 126 people with a Karnofsky PS of 60 or higher to receive paclitaxel (175 mg/m<sup>2</sup>) on day one and carboplatin (350 mg/m<sup>2</sup>) on day one or paclitaxel (175 mg/m<sup>2</sup>) on days one and eight and cisplatin (100 mg/m<sup>2</sup>) on day one. Treatments were repeated every four weeks. </p> <p><a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a> randomised 176 people with a Karnofsky PS of 70 or higher to receive gemcitabine (1200 mg/m<sup>2</sup>) on days one and eight and intravenous cisplatin (80 mg/m<sup>2</sup>) on day one, or gemcitabine (1200 mg/m<sup>2</sup>) and carboplatin (AUC 5 mg/mL X min) on day one. Treatments were repeated every three weeks. The primary outcome of the trial was toxicity. </p> </section> <section id="CD009256-sec-0078"> <h4 class="title">Excluded studies</h4> <p>In this update, we excluded seven publications from the first selection after full‐text analysis due to the following reasons: three were not RCTs (<a href="./references#CD009256-bbs2-0016" title="SunX , ZhengY . Cisplatin or carboplatin for advanced non–small cell lung cancer?. Journal of Thoracic Oncology2014;9(9):e70. ">Sun 2014</a>; <a href="./references#CD009256-bbs2-0017" title="TiseoM , ArdizzoniA , BoniL . First‐line chemotherapy treatment of advanced non–small‐cell lung cancer. Does cisplatin versus carboplatin make a difference?. Journal of Thoracic Oncology2014;9(11):e82. ">Tiseo 2014</a>; <a href="./references#CD009256-bbs2-0018" title="vonVerschuerU , SchnellR , TessenHW , EggertJ , BinningerA , SpringL , et al. Treatment, outcome and quality of life of 1239 patients with advanced non‐small cell lung cancer – final results from the prospective German TLK cohort study. Lung Cancer2017;112:216‐24. ">von Verschuer 2017</a>); one presented a post hoc analysis of an RCT (<a href="./references#CD009256-bbs2-0015" title="SmitE , Moro‐SibilotD , deCastro CarpeñoJ , Lesniewski‐KmakK , AertsJ , VillatoroR , et al. Cisplatin and carboplatin‐based chemotherapy in the first‐line treatment of non‐small cell lung cancer: analysis from the European FRAME study. Lung Cancer2016;92:35‐40. ">Smit 2016</a>); one evaluated platinum versus non‐platinum chemotherapy (<a href="./references#CD009256-bbs2-0013" title="Moro‐SibilotD , Audigier‐ValetteC , MerleP , QuoixE , SouquetPJ , BarlesiF , et al. Non‐small cell lung cancer recurrence following surgery and perioperative chemotherapy: comparison of two chemotherapy regimens (IFCT‐0702: a randomized phase 3 final results study). Lung Cancer2015;89(2):139‐45. ">Moro‐Sibilot 2015</a>); one presented a quality of life analysis of another trial (<a href="./references#CD009256-bbs2-0012" title="BillinghamL , GauntP , JarrettHW , DunlopD , ThompsonD , O’ByrneKJ , et al. Quality of life in advanced non‐small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. Thorax2011;66:A41. ">Billingham 2011</a>); and one was neither designed nor powered to perform a direct comparison between different platinum regimens (<a href="./references#CD009256-bbs2-0014" title="SchuetteWH , GröschelA , SebastianM , AndreasS , MüllerT , SchnellerF , et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first‐line therapy for patients with locally advanced or metastatic non‐small‐cell lung cancer. Clinical Lung Cancer2013;14(3):215‐23. ">Schuette 2013</a>). </p> <p>See <a href="./references#CD009256-sec-0134" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD009256-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD009256-sec-0080"> <h4 class="title">Allocation</h4> <p>Allocation was adequately concealed in 8 of 11 included trials (<a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>; <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>; <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>; <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a>). The information about allocation concealment in two Chinese RCTs was unclear, and we could not contact the authors (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>). <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a> was an open‐label study. </p> </section> <section id="CD009256-sec-0081"> <h4 class="title">Blinding</h4> <section id="CD009256-sec-0082"> <h5 class="title">Blinding of participants (performance bias)</h5> <p>None of the 11 RCTs reported complete information about the blinding processes. <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a> and <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> were open‐label studies and were considered to have high risk of performance bias related to the blinding of participants. Nine trials reported no information related to blinding processes (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>; <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>; <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>; <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a>), and we were unable to obtain details about blinding through contact with the authors; we therefore judged these trials as at unclear risk for blinding of participants. </p> </section> <section id="CD009256-sec-0083"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>None of the 11 RCTs reported complete information about the blinding processes. <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a> and <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> were open‐label studies and were considered to have high risk of detection bias related to the blinding of the outcome assessment process. Nine trials reported no information related to blinding processes (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>; <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>; <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>; <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a>), and we were unable to obtain details about blinding through contact with the authors; we therefore judged these trials as at unclear risk for blinding of outcome assessment. </p> </section> </section> <section id="CD009256-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>Fifteen of 1218 participants in <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> did not receive treatment (nine were ineligible, four withdrew consent, and two died of malignant disease before the first drug infusion), thus we excluded these participants from the safety analysis. </p> <p>In <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>, the study design was amended to include only participants with an ECOG PS 0 or 1 after the enrolment of 66 participants with an ECOG PS 2. These participants were not included in the final analysis, which could have affected the results since people with a ECOG PS 2 have a poorer prognosis, and the numbers of these participants in each arm were not reported. </p> <p>Of the 618 participants randomised in <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>, 10 (2%) did not receive a study drug (three in the carboplatin arm and seven in the cisplatin arm), but we considered this unlikely to result in a significant bias. </p> </section> <section id="CD009256-sec-0085"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a> reported no survival data and was excluded from the analysis of overall survival and one‐year survival rate. </p> <p><a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a> reported no overall survival data but did provide one‐year survival rate. </p> <p>The remaining studies reported overall survival data only as median and confidence intervals, therefore we converted them to hazard ratios, according to the method proposed by <a href="./references#CD009256-bbs2-0040" title="ParmarMKB , ValterT , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>. </p> <p>In the analysis of adverse effects that were measured as number of events per cycle, alopecia was not mentioned in <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a> and renal toxicity analysis was not performed by <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>. </p> <p>In the analysis of adverse effects that were measured as events per participant, nausea, vomiting, or both were not evaluated by <a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>, which was the only RCT to describe the incidence of skin rash. Only <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a> and <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a> analysed the incidence of alopecia. Five studies evaluated neurotoxicity (<a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>; <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0011" title="ZatloukalP , PetruzelkaL , ZemanováM , KolekV , SkrickováJ , PesekM , et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non‐small cell lung cancer: a phase III randomized trial. Lung Cancer2003;41(3):321‐31. ">Zatloukal 2003</a>). </p> </section> <section id="CD009256-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p>It is important to note that <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> used the Wright formula for calculation of creatinine clearance, which usually results in about 10% higher doses of carboplatin than with the use of the Cockcroft‐Gault formula (<a href="./references#CD009256-bbs2-0050" title="WrightJ , BoddyA , HighleyM , FenwickJ , McGillA , CalvertA . Estimation of glomerular filtration rate in cancer patients. British Journal of Cancer2001;84(4):452‐9. ">Wright 2001</a>). </p> <p>Six trials were planned as randomised phase II studies, therefore the findings obtained from the treatment arm comparisons should be considered exploratory (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0002" title="ChenYM , PerngRP , TsaiCM , Whang‐PengJ . A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo‐naive inoperable non‐small cell lung cancer in the elderly. Journal of Thoracic Oncology2006;1(2):141‐5. ">Chen 2006</a>; <a href="./references#CD009256-bbs2-0005" title="MazzantiP , MassacesiC , RocchiMB , MattioliR , LippeP , TrivisonneR , et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non‐small cell lung cancer. Lung Cancer2003;41(1):81‐9. ">Mazzanti 2003</a>; <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a>; <a href="./references#CD009256-bbs2-0009" title="SweeneyCJ , ZhuJ , SandlerAB , SchillerJ , BelaniCP , LangerC , et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer2001;92(10):2639‐47. ">Sweeney 2001</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>). </p> <p>In <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>, a reduction of carboplatin dose was necessary for 96 of 279 (34%) participants randomised to the drug, and the mean dose AUC for them was 4.9 mg/mL X min. This dose could be associated with a lower effectiveness. </p> <p>In <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>, the paclitaxel dose (135 mg/m<sup>2</sup>and 225 mg/m<sup>2</sup>) and length of infusion (24 and 3 hours) were different, which could have compromised the comparison in efficacy and toxicity. </p> </section> </section> <section id="CD009256-sec-0087"> <h3 class="title" id="CD009256-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD009256-tbl-0001"><b>Summary of findings for the main comparison</b> Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</a> </p> <section id="CD009256-sec-0088"> <h4 class="title">Carboplatin‐based versus cisplatin‐based chemotherapy</h4> <p>The table 1 summarize the main results regarding the comparison of carboplatin with cisplatin chemotherapy in combination with third‐generations drugs for advanced non‐small cell lung cancer (<a href="./full#CD009256-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD009256-sec-0089"> <h5 class="title">Overall survival (Analysis 1.1)</h5> <p>Overall survival was evaluated by 10 RCTs, and the meta‐analysis found no difference between cisplatin‐ and carboplatin‐based chemotherapy (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.82 to 1.20; 10 RCTs; 2515 participants;; high‐quality evidence) (<a href="./references#CD009256-fig-0007" title="">Analysis 1.1</a>, <a href="#CD009256-fig-0003">Figure 3</a>). There was no significant heterogeneity amongst RCTs. </p> <div class="figure" id="CD009256-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.1 Overall survival." data-id="CD009256-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> </div> <section id="CD009256-sec-0090"> <h6 class="title">Subgroup analysis</h6> <p>The subgroup analysis considering the combined drug was consistent with the main result for gemcitabine (HR 0.99, 95% CI 0.82 to 1.20; 5 RCTs; 367 participants; ); paclitaxel (HR 1.00, 95% CI 0.37 to 2.73; 4 RCTS;1334 participants; ); and docetaxel (HR 1.01, 95% CI 0.16 to 6.37; 1 RCT; 814 participants). </p> </section> </section> <section id="CD009256-sec-0091"> <h5 class="title">Quality of life analysis</h5> <p>Two RCTs performed a QoL analysis. <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> evaluated QoL using the EORTC QLQ‐LC13 and the Lung Cancer Symptom Scale (LCSS) questionnaires but did not compare cisplatin and carboplatin arms directly. <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a> applied the QLQ‐C30 and QOL‐LC13 questionnaires to compare the two drugs and found no significant differences in global health status or in functional scales. Because of this paucity of QoL data, we could not perform a meta‐analysis. <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a> reported comparative QoL data between the study arms, but found no significant differences in global indices of quality of life, including global health status or the functional scales. However, the cisplatin‐containing arm was associated with a higher rate of appetite loss (P = 0.084), whilst participants in the arm containing carboplatin reported haemoptysis more frequently (P = 0.048); pain and chest pain (P = 0.058 and P = 0.046, respectively); and required greater pain medication consumption (P = 0.054). </p> </section> <section id="CD009256-sec-0092"> <h5 class="title">One‐year survival rate (Analysis 1.2)</h5> <p>One‐year survival rate was evaluated in 11 RCTs, and no difference was found between cisplatin‐ and carboplatin‐based chemotherapy (risk ratio (RR) 0.98, 95% CI 0.89 to 1.08; 11 RCTS; 4004 participants; high‐quality evidence) (<a href="./references#CD009256-fig-0008" title="">Analysis 1.2</a>, <a href="#CD009256-fig-0004">Figure 4</a>). No significant heterogeneity was detected amongst RCTs. </p> <div class="figure" id="CD009256-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.2 1‐year survival rate." data-id="CD009256-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.2 1‐year survival rate. </p> </div> </div> </div> <section id="CD009256-sec-0093"> <h6 class="title">Subgroup analysis</h6> <p>The subgroup analysis considering the companion drugs was consistent with the main result for paclitaxel (RR 0.97, 95% CI 0.84 to 1.12; 5 RCTS; 1460 participants; I<sup>2</sup> = 0%) and gemcitabine (RR 1.10, 95% CI 0.97 to 1.25; 5 RCTS; 1730 participants; I<sup>2</sup> = 0%). However, one RCT found benefit with the cisplatin‐based regimen with docetaxel (RR 0.82, 95% CI 0.70 to 0.97; 1 RCT; 814 participants) (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>). </p> </section> </section> <section id="CD009256-sec-0094"> <h5 class="title">Response rate (Analysis 1.3)</h5> <p>All 11 RCTs evaluated response rate (5088 participants; 4020 pooled for meta‐analysis). Meta‐analysis showed that there was no difference in response rate between cisplatin‐ and carboplatin‐based chemotherapy (RR 0.89, 95% CI 0.79 to 1.00; I<sup>2</sup> = 12%) (<a href="./references#CD009256-fig-0009" title="">Analysis 1.3</a>, <a href="#CD009256-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009256-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.3 Response rate." data-id="CD009256-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.3 Response rate. </p> </div> </div> </div> <section id="CD009256-sec-0095"> <h6 class="title">Subgroup analysis</h6> <p>Overall, the subgroup analyses according to different third‐generation drugs used did not showed superiority regarding the platinum agent used. The response rates in five trials (1436 participants) with cisplatin or carboplatin combined with paclitaxel (RR 0.89, 95% CI 0.74 to 1.07; I<sup>2</sup> = 0%) as also in five trials (1770 available participants) combined with gemcitabine (RR 0.92, 95% CI 0.74 to 1.15; I<sup>2</sup> = 32%) did not demonstraded statistical significant difference between cisplatin or carboplatin. One exception was a cisplatin superiority over carboplatin regarding docetaxel doublet (RR 0.76, 95% CI 0.60 to 0.95) in the only trial (814 participants) that used docetaxel (Fossella 2003). </p> </section> </section> <section id="CD009256-sec-0096"> <h5 class="title">Drug toxicity ‐ grade III or IV toxicity as events per cycle (Analysis 1.4)</h5> <p>Eleven RCTs assessed this outcome. The rates of adverse effects were reported as number of events per participant or events per cycle. Since nine RCTs reported data as per participant and two trials as per treatment cycle, we analysed them separately and only considered grade III and IV toxicities (<a href="./references#CD009256-fig-0010" title="">Analysis 1.4</a>) </p> <p>A meta‐analysis of two trials that evaluated toxicity as events per cycle found a higher incidence of anaemia (RR 4.51, 95% CI 2.96 to 6.89; I<sup>2</sup> = 0%) and neutropenia (RR 4.22, 95% CI 1.56 to 11.37; I<sup>2</sup> = 87%) in the carboplatin arm. There was no difference in the incidence of nausea or vomiting (or both) (RR 0.77, 95% CI 0.28 to 2.12; I<sup>2</sup> = 81%); renal toxicity (RR 0.33, 95% CI 0.01 to 7.99); or neurotoxicity (RR 0.20, 95% CI 0.01 to 4.07). The heterogeneity found in the neutropenia and nausea/vomiting analysis could be explained by the difference in the risk of neutropenia and the large differences in sample sizes. </p> </section> <section id="CD009256-sec-0097"> <h5 class="title">Drug toxicity ‐ grade III or IV toxicity as events per participant (Analysis 1.5)</h5> <p>We performed a meta‐analysis of 10 RCTs that evaluated toxicity as events per participant and found a higher incidence of thrombocytopenia (RR 2.46, 95% CI 1.49 to 4.04; I<sup>2</sup> = 68%) and neurotoxicity (RR 1.42, 95% CI 0.91 to 2.23; I<sup>2</sup> = 0%) in the carboplatin‐based treatment arms. The heterogeneity found in this analysis was due to data from the <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> trial; when data from this trial were excluded, the result remained similar, but without significant heterogeneity (RR 2.00, 95% CI 1.37 to 2.91; I<sup>2</sup> = 21%). </p> <p>There was no significant difference in the incidence of nausea or vomiting (or both) (RR 0.59, 95% CI 0.31 to 1.11; I<sup>2</sup> = 86%); renal toxicity (RR 0.52, 95% CI 0.19 to 1.45; I<sup>2</sup> = 3%); skin rash (RR 3.00, 95% CI 0.13 to 69.52; I<sup>2</sup> = 0%); alopecia (RR 1.11, 95% CI 0.73 to 1.68; I<sup>2</sup> = 0%); anaemia (RR 1.37, 95% CI 0.79 to 2.38; I<sup>2</sup> = 77%); and neutropenia (RR 1.18, 95% CI 0.85 to 1.63; I<sup>2</sup> = 94%) between cisplatin‐ and carboplatin‐based chemotherapy regimens. In this context, the heterogeneity found could be due to the different toxicity profiles of the other drugs used in association with the platinum compounds. </p> <section id="CD009256-sec-0098"> <h6 class="title">Subgroup analysis</h6> <p>When considering only trials using paclitaxel, the cisplatin‐based treatment arms showed a higher incidence of nausea or vomiting (or both) (RR 0.45, 95% CI 0.26 to 0.77; I<sup>2</sup> = 53%). Heterogeneity in nausea or vomiting (or both) was due mainly to <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>, the only trial that had a greater incidence of nausea or vomiting (or both) in the carboplatin arm. We performed a sensitivity analysis excluding <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a> and obtained a similar estimate of effect but with no heterogeneity (RR 0.36, 95% CI 0.28 to 0.46; I<sup>2</sup> = 0%). Historically, cisplatin has been associated with a higher rate of nausea and vomiting when compared with carboplatin, but in <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a> carboplatin caused more nausea or vomiting (or both). There was no specific reason for this, but one hypothesis is the use of carboplatin in a fixed dose (300 mg/m<sup>2</sup>) rather than an AUC dose. </p> <p>Subgroup analysis including trials with paclitaxel showed a higher incidence of thrombocytopenia (RR 2.34, 95% CI 1.51 to 3.63; I<sup>2</sup> = 0%), but no significant difference in neutropenia (RR 0.91, 95% CI 0.73 to 1.15; I<sup>2</sup> = 62%) or anaemia (RR 0.82, 95% CI 0.60 to 1.14; I<sup>2</sup> = 0%) between treatment arms. The significant heterogeneity in analysis of neutropenia may be explained by the fact that the two larger trials had opposite estimates of effect. After excluding only <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>, we found a similar incidence of neutropenia (RR 0.83, 95% CI 0.58 to 1.18; I<sup>2</sup> = 30%; 4 trials) as well as after removing only <a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a> from the analysis (RR 0.94, 95% CI 0.60 to 1.46; I<sup>2</sup> = 43%; 4 trials). </p> </section> </section> </section> <section id="CD009256-sec-0099"> <h4 class="title">Subgroup analysis (cisplatin dose)</h4> <p>* Carboplatin‐based versus cisplatin‐based chemotherapy administred in low dose (40 to 80mg/m2) or high dose (80 to 100mg/m2) </p> <section id="CD009256-sec-0100"> <h5 class="title">Overall survival (Analysis 2.1)</h5> <section id="CD009256-sec-0101"> <h6 class="title">Carboplatin versus cisplatin (40 to 80 mg/m<sup>2</sup>) </h6> <p>Meta‐analysis of six RCTs (4008 participants; 2508 available for pooling) showed a significant difference between carboplatin and the lower dose of cisplatin (40 to 80 mg/m<sup>2</sup>) in terms of overall survival (HR 1.15, 95% CI 1.03 to 1.28; I<sup>2</sup> = 0%), favouring carboplatin‐based therapy (<a href="./references#CD009256-fig-0012" title="">Analysis 2.1</a>, <a href="#CD009256-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD009256-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2), outcome: 2.1 Overall survival." data-id="CD009256-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m<sup>2</sup> versus 80 to 100 mg/m<sup>2</sup>), outcome: 2.1 Overall survival. </p> </div> </div> </div> </section> <section id="CD009256-sec-0102"> <h6 class="title">Carboplatin versus cisplatin (80 to 100 mg/m<sup>2</sup>) </h6> <p>Meta‐analysis of four RCTs (2277 participants; 1823 available for pooling) comparing carboplatin and the higher dose of cisplatin (80 to 100 mg/m<sup>2</sup>) showed no difference in overall survival (HR 0.93, 95% CI 0.83 to 1.04; I<sup>2</sup> = 0%) (<a href="./references#CD009256-fig-0012" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD009256-sec-0103"> <h5 class="title">One‐year survival (Analysis 2.2)</h5> <section id="CD009256-sec-0104"> <h6 class="title">Carboplatin versus cisplatin (40 to 80 mg/m<sup>2</sup>) </h6> <p>Meta‐analysis of six RCTs (4008 participants; 2508 available for pooling) showed no difference between carboplatin and the lower dose of cisplatin in one‐year survival rates (RR 1.04, 95% CI 0.85 to 1.27; I<sup>2</sup> = 61%) (<a href="./references#CD009256-fig-0013" title="">Analysis 2.2</a>). </p> <p>Since <a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a> was the only trial with a higher one‐year survival rate in the cisplatin arm and was the only trial using docetaxel in doublet, we performed an analysis excluding this trial and obtained a higher one‐year survival in the carboplatin arm without heterogeneity (RR 1.18, 95% CI 1.03 to 1.34; I<sup>2</sup> = 0%). </p> </section> <section id="CD009256-sec-0105"> <h6 class="title">Carboplatin versus cisplatin (80 to 100 mg/m<sup>2</sup>) </h6> <p>A meta‐analysis of five RCTs (2403 participants; 1949 available for pooling) found no statistically significant differences between carboplatin and the higher dose of cisplatin in one‐year survival rate (RR 0.96, 95% CI 0.86 to 1.08; I<sup>2</sup> = 0%) (<a href="./references#CD009256-fig-0013" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD009256-sec-0106"> <h5 class="title">Response rate (Analysis 2.3)</h5> <section id="CD009256-sec-0107"> <h6 class="title">Carboplatin versus cisplatin (40 to 80 mg/m<sup>2</sup>) </h6> <p>Meta‐analysis of seven RCTs (4048 participants; 2524 available for pooling) showed no statistically significant differences between carboplatin and the lower dose of cisplatin in response rate (RR 0.94, 95% CI 0.74 to 1.20; I<sup>2</sup> = 58%). The heterogeneity found in this analysis was due to data from the lower dose cisplatin (50 mg/m<sup>2</sup>) arm of the <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> trial. Re‐analysis after exclusion of these data demonstrated a higher response rate favouring cisplatin‐based chemotherapy without significant heterogeneity (RR 0.81, 95% CI 0.69 to 0.96; I<sup>2</sup> = 0%) (<a href="./references#CD009256-fig-0014" title="">Analysis 2.3</a>). </p> </section> <section id="CD009256-sec-0108"> <h6 class="title">Carboplatin versus cisplatin (80 to 100 mg/m<sup>2</sup>) </h6> <p>Meta‐analysis of five trials (2403 participants; 1949 available for pooling) comparing carboplatin to the higher dose of cisplatin (80 to 100 mg/m<sup>2</sup>) found no difference in response rate (RR 0.89, 95% CI 0.77 to 1.02; I<sup>2</sup> = 0%) (<a href="./references#CD009256-fig-0014" title="">Analysis 2.3</a>). </p> </section> </section> </section> <section id="CD009256-sec-0109"> <h4 class="title">Sensitivity analysis</h4> <section id="CD009256-sec-0110"> <h5 class="title">Fixed‐effect model (Analysis 3.1; Analysis 3.2; Analysis 3.3)</h5> <p>When we performed fixed‐effect analyses, we found no significant differences in overall survival (HR 0.99, 95% CI 0.82 to 1.20) (<a href="./references#CD009256-fig-0015" title="">Analysis 3.1</a>) or one‐year survival rates (RR 0.98, 95% CI 0.91 to 1.07; I<sup>2</sup> = 17%) (<a href="./references#CD009256-fig-0016" title="">Analysis 3.2</a>), although there was a marginally positive benefit in response rates favouring cisplatin‐based treatments (RR 0.89, 95% CI 0.81 to 0.99; I<sup>2</sup> = 12%) (<a href="./references#CD009256-fig-0017" title="">Analysis 3.3</a>). </p> </section> <section id="CD009256-sec-0111"> <h5 class="title">Phase III trials (Analysis 4.1; Analysis 4.2; Analysis 4.3)</h5> <p>When we limited the analysis to phase III trials, there were minimal changes in the results and no significant differences in terms of overall survival (HR 0.99, 95% CI 0.45 to 2.17) (<a href="./references#CD009256-fig-0018" title="">Analysis 4.1</a>); one‐year survival rates (RR 0.97, 95% CI 0.84 to 1.13) (<a href="./references#CD009256-fig-0019" title="">Analysis 4.2</a>); and response rates (RR 0.86, 95% CI 0.71 to 1.03) (<a href="./references#CD009256-fig-0020" title="">Analysis 4.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009256-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009256-sec-0112"></div> <p>Since the 1990s, many trials have been published comparing chemotherapy with best supportive care in people with advanced NSCLC and have consolidated the role of chemotherapy as a means of increasing survival and improving quality of life (<a href="./references#CD009256-bbs2-0037" title="NSCLC Collaborative Group. Chemotherapy in non‐small cell lung cancer: a meta‐analysis using updated data on individual patients from 52 randomised clinical trials. BMJ1995;311(7010):899‐909. ">NSCLC Collaborative Group 1995</a>). Since then, cumulative histopathological advances have allowed a first subdivision with therapeutic implication of NSCLC: squamous and non‐squamous NSCLC. Furthermore, a deeper understanding of the molecular pathways involved in the pathogenesis of NSCLC has permitted the expansion of the number of molecular alterations/driver genes predictive of response to targeted therapy, including epidermal growth factor receptor (<i>EGFR</i> ), anaplastic lymphoma kinase (<i>ALK</i> ), ROS proto‐oncogene 1, receptor tyrosine kinase (<i>ROS1</i> ), MET proto‐oncogene, receptor tyrosine kinase (<i>MET</i> ), ret proto‐oncogene (<i>RET</i> ), B‐Raf proto‐oncogene, serine/threonine kinase (<i>BRAF</i> ), neurotrophic tyrosine receptor kinase <i>(NTRK)</i> , and human epidermal growth factor receptor 2 (<i>HER‐2</i>) (<a href="./references#CD009256-bbs2-0026" title="GridelliC , RossiA , CarboneDP , GuarizeJ , KarachaliouN , MokT , et al. Non‐small‐cell lung cancer. Nature Reviews Disease Primers2015;1(May 21;1:15009):1:16. [DOI: 10.1038/nrdp.2015.9] ">Gridelli 2015</a>). In the presence of these biomarkers, target therapies have been established as standard first‐line treatment options. More recently, immune checkpoint inhibitors have been incorporated into first‐line systemic therapy of patients with advanced NSCLC, and some patients have sustained a clinical response.) As a way of optimising the results obtained with immunotherapy, combinations of cytotoxic chemotherapy and immune checkpoints inhibitors have already been approved for some specific subgroups, reinforcing the role of chemotherapy in the treatment of these patients, either alone or in combination with other therapeutic modalities (<a href="./references#CD009256-bbs2-0032" title="ReckM , Rodríguez‐AbreuD , RobinsonAG , HuiR , CsősziT , FülöpA , et al. KEYNOTE‐024 Investigators. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. New England Journal of Medicine2016;375(19):1823‐33. ">Keynote‐024</a>; <a href="./references#CD009256-bbs2-0033" title="GandhiL , Rodríguez‐AbreuD , GadgeelS , EstebanE , FelipE , DeAngelisF , et al. KEYNOTE‐189 Investigators. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. New England Journal of Medicine2018;378(22):2078‐92. [DOI: 10.1056/NEJMoa1801005] ">Keynote‐189</a>). In view of the palliative intent of the treatment of patients with metastatic NSCLC, the challenge thus remains to find the most effective therapies with the lowest risk of serious adverse effects. </p> <p>We performed an update of a previously published meta‐analysis of trials comparing regimens including cisplatin plus a third‐generation drug with regimens including carboplatin plus a third‐generation drug (<a href="./references#CD009256-bbs2-0051" title="deCastriaTB , daSilvaEM , GoisAF , RieraR . Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2] ">de Castria 2013</a>). In addition to the 10 previously included studies, we added data from one more study, <a href="./references#CD009256-bbs2-0007" title="SaadAS , GhaliRR , ShawkiMA . A prospective randomized controlled study of cisplatin versus carboplatin‐based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics2017;13(2):198‐203. ">Saad 2017</a>, and the final data from the publication of the British Thoracic Oncology Group (BTOG2) trial (<a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a>). </p> <p>We found no significant difference between cisplatin‐ and carboplatin‐based regimens in terms of overall survival, one‐year survival, or response rate. As in the previous version of this review (<a href="./references#CD009256-bbs2-0051" title="deCastriaTB , daSilvaEM , GoisAF , RieraR . Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2] ">de Castria 2013</a>), other meta‐analyses have shown that cisplatin‐based regimens could be slightly more effective in terms of response rate (<a href="./references#CD009256-bbs2-0019" title="ArdizzoniA , BoniL , TiseoM , FossellaFV , SchillerJH , PaesmansM , et al. Cisplatin versus carboplatin‐based chemotherapy in first‐line treatment of advanced non‐small‐cell lung cancer: an individual patient data meta‐analysis. Journal of the National Cancer Institute2007;99(11):847‐57. ">Ardizzoni 2007</a>; <a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a>). However, this finding was not reproduced in the current update. Of note, the improved response rate previously demonstrated could be attributed mainly to one trial, which was the only trial with a significantly higher response rate for cisplatin (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>). Docetaxel was used in both arms of this trial, even though paclitaxel and gemcitabine are generally preferred because of their better tolerability and are used in almost all modern trials. </p> <p>Interestingly, a subgroup analysis investigating the different doses of cisplatin used showed an overall survival benefit in favour of carboplatin‐based regimens when compared to cisplatin at low doses (40 to 80 mg/m<sup>2</sup>). However, this benefit was not confirmed when carboplatin‐based regimens were compared with schedules using higher doses of cisplatin (80 to 100 mg/m<sup>2</sup>). No differences in one‐year survival rates or response rates were demonstrated when comparing carboplatin‐based regimens with different doses of cisplatin. </p> <p>Since only two RCTs evaluated QoL, a meta‐analysis was not possible (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>). This was also a challenge to the authors of previous meta‐analyses because different scores were used (<a href="./references#CD009256-bbs2-0019" title="ArdizzoniA , BoniL , TiseoM , FossellaFV , SchillerJH , PaesmansM , et al. Cisplatin versus carboplatin‐based chemotherapy in first‐line treatment of advanced non‐small‐cell lung cancer: an individual patient data meta‐analysis. Journal of the National Cancer Institute2007;99(11):847‐57. ">Ardizzoni 2007</a>; <a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a>; <a href="./references#CD009256-bbs2-0031" title="JiangJ , LiangX , ZhouX , HuangR , ChuZ . A meta‐analysis of randomized controlled trials comparing carboplatin‐based to cisplatin‐based chemotherapy in advanced non‐small cell lung cancer. Lung Cancer2007;57(3):348‐58. ">Jiang 2007</a>), and some questionnaires could be used only in the countries in which a translated version of the QoL tool with validation was available. Moreover, no trial has compared QoL with cisplatin and carboplatin directly. </p> <p>Different criteria were applied to evaluate response rate, including RECIST, Southwest Oncology Group (SWOG), WHO, and ECOG criteria. Furthermore, different doses of drugs were used in these trials, which could have modified the assessment of effect. </p> <p>Nowadays, the role of histology as a predictor of response and toxicity to different therapies is well recognised (e.g. non‐squamous histology and pemetrexed treatment) (<a href="./references#CD009256-bbs2-0046" title="ScagliottiV , ParikhP , vonPawelJ , BiesmaB , VansteenkisteJ , ManegoldC , et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. Journal of Clinical Oncology2008;26:3543‐51. ">Scagliotti 2008</a>). However, it was not possible to assess the role of histology or other molecular biomarkers in our analysis, since these factors were not evaluated by the majority of the included studies. </p> <p>In this review, carboplatin‐based chemotherapy appeared to be associated with a higher incidence of neurotoxicity. However, there was only one trial that showed a significantly higher incidence of neurotoxicity in the carboplatin arm (<a href="./references#CD009256-bbs2-0008" title="SchillerJH , HarringtonD , BelaniCP , LangerC , SandlerA , KrookJ , et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. New England Journal of Medicine2002;346(2):92‐8. ">Schiller 2002</a>). This is almost certainly because participants in the carboplatin arm received 225 mg/m<sup>2</sup> of paclitaxel, whereas participants in the cisplatin arm received only 135 mg/m<sup>2</sup> of paclitaxel. Since paclitaxel is known to cause dose‐related neurotoxicity, this is likely to be a confounding factor in the final analysis. </p> <p>Although we did not obtain data on second‐line therapies, it is possible that some of the included participants crossed over to another therapy when the disease progressed. The effect of such a cross‐over on the results of this systematic review is unknown and may have affected survival results. </p> <p>Based on results from trials with combination therapies, many patients with advanced NSCLC are currently being treated with cytotoxic chemotherapy in combination with other types of systemic treatments, including immune checkpoint inhibitors and bevacizumab, a recombinant humanised monoclonal antibody that binds vascular endothelial growth factor (<a href="./references#CD009256-bbs2-0045" title="SandlerA , GrayR , PerryMC , BrahmerJ , SchillerJH , DowlatiA , et al. Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer. New England Journal of Medicine2006;355(24):2542‐50. ">Sandler 2006</a>; <a href="./references#CD009256-bbs2-0043" title="ReckM , vonPawelJ , ZatloukalP , RamlauR , GorbounovaV , HirshV , et al. Overall survival with cisplatin‐gemcitabine and bevacizumab or placebo as first‐line therapy for nonsquamous non‐small‐cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology2010;21(9):1804‐9. ">Reck 2010</a>). Since our study was not designed to evaluate the interaction between cytotoxic chemotherapy and other therapies, the question remains as to whether there would be any advantage in favour of some of the platinum salts as a better companion therapy in combination with anti‐angiogenics or immunotherapy in the treatment of advanced NSCLC. </p> <section id="CD009256-sec-0113"> <h3 class="title" id="CD009256-sec-0113">Summary of main results</h3> <p>We obtained data on 4046 participants in 11 RCTs. The included trials had at least one treatment arm with cisplatin and one treatment arm with carboplatin, both combined with paclitaxel (five trials), gemcitabine (five trials), or docetaxel (one trial). </p> <p>There was no difference in overall survival (HR 0.99, 95% CI 0.82 to 1.20); one‐year survival rate (RR 0.98, 95% CI 0.89 to 1.08; I<sup>2</sup> = 17%); or response rate (RR 0.89, 95% CI 0.79 to 1.00; I<sup>2</sup> = 12%). </p> <p>For grade III to IV toxicity measured as events per participant, we detected a higher incidence of thrombocytopenia (RR 2.46, 95% CI 1.49 to 4.04; I<sup>2</sup> = 68%) and neurotoxicity (RR 1.42, 95% CI 0.91 to 2.23; I<sup>2</sup> = 0%) in the carboplatin‐based treatment arms, although the neurotoxicity results were likely related to a confounding factor (higher dose of paclitaxel in the carboplatin‐based treatment group in a large study). </p> <p>We also performed a subgroup analysis comparing carboplatin with different doses of cisplatin: lower dose (40 to 80 mg/m<sup>2</sup>) and higher dose (80 to 100 mg/m<sup>2</sup>). We found an overall survival benefit in favour of carboplatin‐based regimens when compared to cisplatin at lower doses (HR 1.15, 95% CI 1.03 to 1.28), although there was no overall survival benefit when carboplatin‐based chemotherapy was compared to cisplatin at higher doses (HR 0.93, 95% CI 0.83 to 1.04). There was no statistically significant difference in terms of one‐year survival rate or response rate between carboplatin and both doses of cisplatin. </p> <p>We could not perform an analysis of QoL in our review because data were provided by only two trials (<a href="./references#CD009256-bbs2-0004" title="FossellaF , PereiraJR , vonPawelJ , PluzanskaA , GorbounovaV , KaukelE , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology2003;21(16):3016‐24. ">Fossella 2003</a>; <a href="./references#CD009256-bbs2-0006" title="RosellR , GatzemeierU , BetticherDC , KepplerU , MachaHN , PirkerR , et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non‐small‐cell lung cancer: a cooperative multinational trial. Annals of Oncology2002;13(10):1539‐49. ">Rosell 2002</a>). </p> </section> <section id="CD009256-sec-0114"> <h3 class="title" id="CD009256-sec-0114">Overall completeness and applicability of evidence</h3> <p>With regard to external validation, the doses of drugs varied amongst analysed trials, which should be considered when selecting treatment. It is also important to note that the trials analysed in our review did not take into account the status of driver gene mutations and predictive factors of benefit to immune checkpoint inhibitors, such as tumour mutational burden and programmed cell death‐ligant 1 (PD‐L1) expression, which are critical in deciding the initial approach in advanced disease. </p> </section> <section id="CD009256-sec-0115"> <h3 class="title" id="CD009256-sec-0115">Quality of the evidence</h3> <p>The categorisation of the quality of the evidence (into high, moderate, low, or very low) reflects the quality of the evidence available for our chosen outcomes in our defined populations of interest. </p> <p>Our review included 11 RCTs. We considered the evidence from the available data to be of high quality for response rate, one‐year survival rate, and overall survival since no significant random sequence generation bias was detected. However, as different doses of drugs were used, and some adverse effects were omitted from analysis in the original trials, we also considered the evidence from the data for adverse effects to be of moderate quality and note that this information should be interpreted cautiously. </p> </section> <section id="CD009256-sec-0116"> <h3 class="title" id="CD009256-sec-0116">Potential biases in the review process</h3> <p>We performed an electronic search of the main databases and extended our search to include meetings of the American Society of Clinical Oncology. It is unknown whether there are other reports of unpublished trials in different languages or presented at different meetings. </p> <p>We found two Chinese trials (<a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>; <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>). We could not obtain data for overall survival or one‐year survival rate for <a href="./references#CD009256-bbs2-0001" title="CaiX , ChenP , YinX , LiQ . Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2002;5(6):427‐8. ">Cai 2002</a>, and there was no information on overall survival in <a href="./references#CD009256-bbs2-0010" title="YanD , WangG , ZhangG , HuC . A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non‐small cell lung cancer. Zhongguo Fei Ai Za Zhi2001;4(3):188‐90. ">Yan 2001</a>. Since both trials recruited small numbers of participants, we concluded that they did not cause a significant bias in survival analysis. </p> <p>We identified no more significant potential biases.</p> </section> <section id="CD009256-sec-0117"> <h3 class="title" id="CD009256-sec-0117">Agreements and disagreements with other studies or reviews</h3> <p>We found no significant difference between cisplatin‐ and carboplatin‐based regimens in terms of overall survival, one‐year survival rate, or response rate. As in the previous version of this review (<a href="./references#CD009256-bbs2-0051" title="deCastriaTB , daSilvaEM , GoisAF , RieraR . Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2] ">de Castria 2013</a>), other meta‐analyses have shown that cisplatin‐based regimens could be slightly more effective in terms of response rate (<a href="./references#CD009256-bbs2-0019" title="ArdizzoniA , BoniL , TiseoM , FossellaFV , SchillerJH , PaesmansM , et al. Cisplatin versus carboplatin‐based chemotherapy in first‐line treatment of advanced non‐small‐cell lung cancer: an individual patient data meta‐analysis. Journal of the National Cancer Institute2007;99(11):847‐57. ">Ardizzoni 2007</a>; <a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a>; <a href="./references#CD009256-bbs2-0031" title="JiangJ , LiangX , ZhouX , HuangR , ChuZ . A meta‐analysis of randomized controlled trials comparing carboplatin‐based to cisplatin‐based chemotherapy in advanced non‐small cell lung cancer. Lung Cancer2007;57(3):348‐58. ">Jiang 2007</a>). However, this finding was not reproduced in the current update. As in our review, none of these meta‐analyses found that the benefit in favour of cisplatin in terms of response rate translated into overall survival gain. </p> <p>In 2004, Hotta and colleagues published a meta‐analysis that included eight trials comparing doublets of cisplatin or carboplatin plus another drug (<a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a>). We included only five of these trials in our analysis because the other three studies used older agents combined with platin. In a subset analysis of trials consisting of a platin plus a third‐generation drug, <a href="./references#CD009256-bbs2-0030" title="HottaK , MatsuoK , UeokaH , KiuraK , TabataM , TanimotoM . Meta‐analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‐small‐cell lung cancer. Journal of Clinical Oncology2004;22(19):3852‐9. ">Hotta 2004</a> found superior survival in the cisplatin arm, and <a href="./references#CD009256-bbs2-0019" title="ArdizzoniA , BoniL , TiseoM , FossellaFV , SchillerJH , PaesmansM , et al. Cisplatin versus carboplatin‐based chemotherapy in first‐line treatment of advanced non‐small‐cell lung cancer: an individual patient data meta‐analysis. Journal of the National Cancer Institute2007;99(11):847‐57. ">Ardizzoni 2007</a> demonstrated a superior HR for mortality in the carboplatin arm. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009256-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009256-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Updated meta‐analysis study flow diagram." data-id="CD009256-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Updated meta‐analysis study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.1 Overall survival." data-id="CD009256-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.2 1‐year survival rate." data-id="CD009256-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.2 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.3 Response rate." data-id="CD009256-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carboplatin‐based versus cisplatin‐based chemotherapy, outcome: 1.3 Response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2), outcome: 2.1 Overall survival." data-id="CD009256-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m<sup>2</sup> versus 80 to 100 mg/m<sup>2</sup>), outcome: 2.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 1 Overall survival." data-id="CD009256-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 2 1‐year survival rate." data-id="CD009256-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 2 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 3 Response rate." data-id="CD009256-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 3 Response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 4 Grade III or IV toxicity by cycle." data-id="CD009256-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 4 Grade III or IV toxicity by cycle. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 5 Grade III or IV toxicity by participant." data-id="CD009256-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Carboplatin‐based versus cisplatin‐based chemotherapy, Outcome 5 Grade III or IV toxicity by participant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2), Outcome 1 Overall survival." data-id="CD009256-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m<sup>2</sup> versus 80 to 100 mg/m<sup>2</sup>), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2), Outcome 2 1‐year survival rate." data-id="CD009256-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m<sup>2</sup> versus 80 to 100 mg/m<sup>2</sup>), Outcome 2 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2), Outcome 3 Response rate." data-id="CD009256-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (cisplatin dose: 40 to 79 mg/m<sup>2</sup> versus 80 to 100 mg/m<sup>2</sup>), Outcome 3 Response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 1 Overall survival." data-id="CD009256-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 2 1‐year survival rate." data-id="CD009256-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 2 1‐year survival rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 3 Response rate." data-id="CD009256-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis (fixed‐effect model), Outcome 3 Response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis (phase III trials), Outcome 1 Overall survival." data-id="CD009256-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis (phase III trials), Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis (phase III trials), Outcome 2 1‐year survival rate." data-id="CD009256-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis (phase III trials), Outcome 2 1‐year survival rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009256-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/urn:x-wiley:14651858:media:CD009256:CD009256-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_t/tCD009256-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis (phase III trials), Outcome 3 Response rate." data-id="CD009256-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis (phase III trials), Outcome 3 Response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/media/CDSR/CD009256/image_n/nCD009256-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009256-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> combination with third‐generation drugs for advanced non‐small cell lung cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> carboplatin‐containing chemotherapy<br/> <b>Comparison:</b> cisplatin‐containing chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with carboplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival</p> <p>(baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Low risk of death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>HR 0.99<br/> (0.82 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2515<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1000<br/> (254 to 348) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>High risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/> (388 to 512) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1‐year survival rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.89 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4004<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/> (330 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.79 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4020<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/> (219 to 277) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.42 (0.91 to 2.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3857<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000<br/> (57 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (1.49 to 4.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3857<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/> (66 to 180) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade III or IV renal toxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/> (0.19 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1272<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (4 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Renal toxicity rates were only reported by five included trials.<br/> <sup>2</sup>The heterogeneity found in this analysis was due to data from the <a href="./references#CD009256-bbs2-0003" title="FerryD , BillinghamL , JarrettH , DunlopD , WollPJ , NicolsonM , et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non‐small‐cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer2017;83:302–12. ">Ferry 2017</a> trial, so that when data from this trial were excluded, the result remained similar, but without significant heterogeneity (RR 2.00, 95% CI 1.37 to 2.91; I<sup>2</sup> = 21%).<br/> <sup>3</sup>Renal toxicity rates were only reported by three included trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/full#CD009256-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009256-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carboplatin‐based versus cisplatin‐based chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Carboplatin vs cisplatin plus gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Carboplatin vs cisplatin plus paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.37, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Carboplatin vs cisplatin plus docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.16, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Carboplatin vs cisplatin plus gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.97, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Carboplatin vs cisplatin plus paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Carboplatin vs cisplatin plus docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Carboplatin vs. cisplatin plus gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Carboplatin vs. cisplatin plus paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Carboplatin vs. cisplatin plus docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade III or IV toxicity by cycle <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nausea, vomiting or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.16, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Renal toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Neurotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.50, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.39, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade III or IV toxicity by participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea, vomiting or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.31, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Renal toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.33, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Neurotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.91, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.73, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.79, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.49, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.85, 1.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carboplatin‐based versus cisplatin‐based chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009256-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 40 to 80 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.03, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 80 to 100 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 40 to 80 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.85, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 80 to 100 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 40 to 80 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 80 to 100 mg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (cisplatin dose: 40 to 79 mg/m2 versus 80 to 100 mg/m2)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009256-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis (fixed‐effect model)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis (fixed‐effect model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009256-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis (phase III trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.45, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 1‐year survival rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.71, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis (phase III trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009256.pub3/references#CD009256-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009256.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009256-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009256-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009256-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD009256-note-0001">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD009256-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009256-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009256-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009256-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009256\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009256\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009256\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009256\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009256\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009256.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009256.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009256.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009256.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009256.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717386434"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009256.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717386438"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009256.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db6a6ce9d9365',t:'MTc0MDcxNzM4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 